Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HJC0152 |
Synonyms | |
Therapy Description |
HJC0152 inhibits STAT3, potentially leading to induction of apoptosis and decreased proliferation, migration, invasion, and tumor growth (PMID: 30588091, PMID: 35085771). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HJC0152 | HJC-0152|HJC 0152 | STAT3 Inhibitor 26 | HJC0152 inhibits STAT3, potentially leading to induction of apoptosis and decreased proliferation, migration, invasion, and tumor growth (PMID: 30588091, PMID: 35085771). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK ALK G1202R | lung non-small cell carcinoma | sensitive | HJC0152 | Preclinical - Cell culture | Actionable | In a preclinical study, HJC0152 treatment decreased Stat signaling, migration, and invasion in a non-small cell lung cancer cell line expressing EML4-ALK and ALK G1202R in culture (PMID: 35085771). | 35085771 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|